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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERPrognostic Value of CMR 1031
Hamza El Aidi, Arthur Adams, Karel G. M. Moons, Hester M. Den Ruijter,
Willem P. Th. M. Mali, Pieter A. Doevendans, Eike Nagel, Simon Schalla, Michiel L. Bots, Tim Leiner
El Aidi and colleagues performed a systematic review to determine the prognostic value of
cardiac magnetic resonance (CMR) for future cardiovascular events in patients with a recent
myocardial infarction (MI) and patients with suspected or known coronary artery disease
(CAD). Fifty-six studies (n ¼ 25,497) were evaluated. For patients with recent MI, there
were not enough events to establish associations between CMR ﬁndings and hard events, but
left ventricular ejection fraction (LVEF) was independently associated with major adverse
cardiac events (MACE). In patients with suspected or known CAD, wall motion
abnormalities, inducible perfusion defects, LVEF, and infarction were each independently
associated with hard events, and the presence of inducible perfusion defects was associated
with MACE.
Commentary: Ilan Gottlieb, Gabriel Camargo, p. 1046CLINICAL RESEARCH ACUTE CORONARY SYNDROMESVorapaxar in ACS Patients Undergoing CABG 1048David J. Whellan, Pierluigi Tricoci, Edmond Chen, Zhen Huang, David Leibowitz,
Pascal Vranckx, Gregary D. Marhefka, Claes Held, Jose C. Nicolau, Robert F. Storey, Witold Ruzyllo,
Kurt Huber, Peter Sinnaeve, A. Teddy Weiss, Jean-Pierre Dery, David J. Moliterno,
Frans Van de Werf, Philip E. Aylward, Harvey D. White, Paul W. Armstrong, Lars Wallentin,
John Strony, Robert A. Harrington, Kenneth W. Mahaffey
Vorapaxar is a protease-activated receptor (PAR)-1 antagonist that was compared with
placebo in patients with acute coronary syndrome in the TRACER (Thrombin Receptor
Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial. In this paper,
Whellan and colleagues assessed the efﬁcacy and safety of vorapaxar among the 10% of
subjects who underwent coronary artery bypass graft (CABG) during index hospitalization.
Compared with placebo-treated CABG patients, vorapaxar-treated patients had a 45% lower
rate of the primary endpointda composite of death, myocardial infarction, stroke, recurrent
ischemia with rehospitalization, or urgent coronary revascularization during index
hospitalization. There were no signiﬁcant differences in rates of major bleeding, fatal
bleeding, or need for reoperation. These data show promise for PAR-1 antagonism in
patients undergoing CABG and warrant conﬁrmatory evidence in randomized trials.
Editorial Comment: Ori Ben-Yehuda, p. 1058(continued on page A-32)
MARCH 25, 2014 (continued) A-32ACUTE CORONARY SYNDROMESPrasugrel or High-Dose Clopidogrel for High Platelet Reactivity After
Clopidogrel Load in ACS Patients
1061Dániel Aradi, Adrienn Tornyos, Tünde Pintér, András Vorobcsuk, Attila Kónyi, József Faluközy,
Gábor Veress, Balázs Magyari, Iván G. Horváth, András Komócsi
Clopidogrel pre-treated acute coronary syndrome (ACS) patients undergoing successful
percutaneous coronary intervention (PCI) were enrolled in a single-center, prospective
registry. Platelet function was measured 12 to 36 h after PCI with the Multiplate device.
Patients with high platelet reactivity (HPR) (>46 U) were switched to prasugrel or were
treated with high-dose clopidogrel. Compared with patients without HPR, the risk of all-
cause death, myocardial infarction, stent thrombosis, or stroke at 1 year was signiﬁcantly
higher in the high-dose clopidogrel group (hazard ratio [HR]: 2.27, p < 0.0001), whereas
HPR patients who switched to prasugrel had similar outcomes. Bleeding Academic Research
Consortium type 3/5 bleeding was also higher with high-dose clopidogrel (HR: 2.09,
p ¼ 0.04) but not for patients who switched to prasugrel. Switching ACS patients with
HPR to prasugrel reduces thrombotic and bleeding events to a level similar to those
without HPR; however, using high-dose clopidogrel results in a higher risk for both
thrombotic and bleeding complications.CARDIOMETABOLIC RISKRisks of AMI and HF in Metabolically-Healthy But Obese Patients 1071
Bjørn Mørkedal, Lars J. Vatten, Pål R. Romundstad, Lars E. Laugsand, Imre Janszky
In a population-based prospective cohort study, 61,299 men and women free from
cardiovascular disease were classiﬁed according to body mass index (BMI) and metabolic
status at baseline. BMI was also measured 10 and 30 years before baseline in about one-third
of participants. Participants were categorized as metabolically unhealthy if they had elevated
waist circumference or BMI >30 kg/m2 in addition to 2 or more of the following criteria:
elevated nonfasting triglycerides, reduced high-density lipoprotein cholesterol, elevated blood
pressure, elevated nonfasting glucose, or a diabetes diagnosis. Compared with normal weight
(BMI <25 kg/m2) and metabolically-healthy individuals, the multivariable-adjusted hazard
ratio (HR) for acute myocardial infarction was 1.1 among obese (BMI 30 kg/m2) and
metabolically-healthy participants, and 2.0 among those who were obese and metabolically
unhealthy. For heart failure (HF), the HRs associated with obesity were 1.7 and 1.7 for
metabolically-healthy and unhealthy participants, respectively. Severe and long-lasting
obesity were particularly harmful in relation to HF, regardless of metabolic status.
Editorial Comment: Carl J. Lavie, Richard V. Milani, Hector O. Ventura, p. 1079(continued on page A-34)
MARCH 25, 2014 (continued) A-34ANTITHROMBOTIC THERAPYCardioversion for AF With Apixaban 1082
Greg Flaker, Renato D. Lopes, Sana M. Al-Khatib, Antonio G. Hermosillo, Stefan H. Hohnloser,
Brian Tinga, Jun Zhu, Puneet Mohan, David Garcia, Jozef Bartunek, Dragos Vinereanu,
Steen Husted, Veli Pekka Harjola, Marten Rosenqvist, John H. Alexander, Christopher B. Granger,
for the ARISTOTLE Committees and Investigators
Flaker and colleagues used data from the ARISTOTLE (Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation) trial to determine the risk of major
clinical and thromboembolic events after cardioversion for atrial ﬁbrillation (AF) in subjects
treated with apixaban or warfarin. A total of 743 cardioversions were performed in the
randomized, double-blind study. No stroke or systemic emboli occurred in the 30-day period
after cardioversion. Myocardial infarction occurred in 1 patient (0.2%) receiving warfarin and
1 patient (0.3%) receiving apixaban. Major bleeding occurred in 1 patient (0.2%) receiving
warfarin and 1 patient (0.3%) receiving apixaban. These results show that major
cardiovascular events after cardioversion of AF are rare and comparable between warfarin and
apixaban.
Editorial Comment: Matthew R. Reynolds, p. 1088HEART VALVE DISEASETAVR Versus SAVR for Diabetic Patients With AS 1090
Brian R. Lindman, Philippe Pibarot, Suzanne V. Arnold, Rakesh M. Suri,
Thomas C. McAndrew, Hersh S. Maniar, Alan Zajarias, Susheel Kodali, Ajay J. Kirtane,
Vinod H. Thourani, E. Murat Tuzcu, Lars G. Svensson, Ron Waksman, Craig R. Smith,
Martin B. Leon
Lindman and colleagues studied whether diabetes affected the relative risks of surgical aortic
valve replacement or transcatheter aortic valve replacement (TAVR) in patients with severe
aortic stenosis (AS) enrolled in the PARTNER (Placement of Aortic Transcatheter Valve)
trial. Among 657 patients enrolled in the PARTNER trial who underwent treatment, there
were 275 patients with diabetes. There was a signiﬁcant interaction between diabetes and
treatment group for 1-year all-cause mortality (p ¼ 0.048). Among diabetic patients, 1-year
all-cause mortality was 18% in the transcatheter group and 27% in the surgical group (hazard
ratio: 0.60). Results were consistent among patients treated via transfemoral or transapical
routes. In contrast, among nondiabetic patients, there was no signiﬁcant difference in all-
cause mortality at 1 year. This post-hoc stratiﬁed analysis of the PARTNER trial suggests
that diabetic patients are more likely to beneﬁt from TAVR than nondiabetic patients.(continued on page A-36)
MARCH 25, 2014 (continued) A-36HEART VALVE DISEASEBleeding Complications After SAVR and TAVR 1100Philippe Généreux, David J. Cohen, Mathew R. Williams, Michael Mack, Susheel K. Kodali,
Lars G. Svensson, Ajay J. Kirtane, Ke Xu, Thomas C. McAndrew, Raj Makkar, Craig R. Smith,
Martin B. Leon
Généreux and colleagues sought to identify the incidence, predictors, and prognostic impact
of bleeding complications (BC) after surgical aortic valve replacement (SAVR) compared
with transcatheter aortic valve replacement (TAVR). In the randomized PARTNER
(Placement of Aortic Transcatheter Valve) trial, 657 patients from cohort A (operable high
risk) were randomly assigned to SAVR or TAVR (transfemoral [TF] if iliofemoral access
was suitable or transapical [TA] if not) and received the designated treatment. A total of
71 (22.7%), 27 (11.3%), and 9 (8.8%) patients had major BC within 30 days of the procedure
after SAVR, TF-TAVR, and TA-TAVR, respectively (p < 0.0001). SAVR was associated
with a signiﬁcantly higher 30-day rate of transfusion. Among high-risk aortic stenosis patients,
BC were more common after SAVR than TAVR and were also associated with a worse
long-term prognosis.
Editorial Comment: Joachim Schofer, p. 1110CARDIAC IMAGINGT1 Mapping and Left Ventricular Stiffness 1112
Andris H. Ellims, James A. Shaw, Dion Stub, Leah M. Iles, James L. Hare, Glenn S. Slavin,
David M. Kaye, Andrew J. Taylor
The purpose of this study was to utilize cardiac magnetic resonance imaging and invasive left
ventricular (LV) pressure-volume measurements to explore the relationship between diffuse
myocardial ﬁbrosis and indexes of diastolic performance in a cohort of cardiac transplant
recipients. Despite normal intracardiac pressures, both post-contrast myocardial T1 time and
extracellular volume fraction correlated with b, the load-independent passive LV stiffness
constant. Following multivariate analysis, post-contrast myocardial T1 time remained the
only independent predictor of b. No signiﬁcant associations were observed between
myocardial T1 time and s, the active LV relaxation constant, or other load-dependent
parameters of diastolic function. In patients with increased diffuse myocardial ﬁbrosis,
abnormal passive ventricular stiffness may be a major contributor to diastolic dysfunction.
Editorial Comment: Christopher T. Sibley, p. 1119
